Altimmune Stock Up More Than 25% in a Month: Here's Why

Altimmune (ALT) is developing its lead candidate, pemvidutide, a novel, investigational and peptide-based GLP-1/glucagon dual receptor agonist for treating obesity and metabolic dysfunction-associated steatohepatitis (MASH).The company has made rapid progress with the development of pemvidutide, which has pushed up its stock price in recent months. A phase IIb IMPACT study is ongoing which is evaluating pemvidutide for the treatment of patients with biopsy-confirmed MASH.Last month, Altimmune completed the ...